Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
Sponsor: Zheng Yabing
Summary
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving chemotherapy. The decision to use mecapegfilgrastim will be made by the treating physician as part of routine clinical care. Participants will be followed to collect information on neutropenia, febrile neutropenia, treatment-related adverse events, and chemotherapy delivery.
Official title: A Real-World Study of Mecapegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2024-10-24
Completion Date
2027-03-31
Last Updated
2026-10-27
Healthy Volunteers
No
Interventions
No Prophylactic G-CSF
No prophylactic granulocyte colony-stimulating factor is administered during the chemotherapy cycle.
Short-acting G-CSF
Short-acting granulocyte colony-stimulating factor is administered prophylactically according to routine clinical practice.
Long-acting G-CSF
Long-acting pegylated recombinant human granulocyte colony-stimulating factor administered prophylactically according to routine clinical practice.
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China